Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Business Wire
Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented in a late-breaking poster presentationAn oral presentation will highlight data from an Investigator Sponsored Trial for domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma, demonstrating further proof of concept for the Fc-silent anti-TIGIT antibody domvanalimabArcus will discuss the ARC-10 results in more detail on its earnings call at 2:00 PM PT / 5:00 PM ET on Wednesday, November 6, 2024 HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Tex
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
- Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Adenosine Antagonists Therapeutics | DelveInsight [Yahoo! Finance]Yahoo! Finance
RCUS
Earnings
- 11/6/24 - Beat
RCUS
Sec Filings
- 12/20/24 - Form 4
- 12/17/24 - Form SC
- 12/17/24 - Form 4
- RCUS's page on the SEC website